EQT Private Capital made a public takeover offer to acquire Swedish CDMO Recipharm AB for SEK 23.6B (~$2.8B). Recipharm provides API and finished pharmaceutical product manufacturing globally. Under EQT ownership the company executed the buyer's stated growth-and-capacity playbook: in 2022 Recipharm acquired Arranta Bio, Vibalogics and Genibet to build advanced-therapeutics and biologics/viral-vector capacity, and in April 2024 it reshaped the portfolio — carving out the Bespak inhalation/advanced-delivery unit into a separate EQT portfolio company and selling seven European manufacturing sites to Blue Wolf Capital Partners.